Chronic viral hepatitis in kidney transplantation

Nature Reviews Nephrology

Volumn 7, Issue 3, 2011, Pages 156-165

  Huskey, Janna ^a   Wiseman, Alexander C ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; TENOFOVIR;

ANTIVIRAL THERAPY; DIALYSIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; KIDNEY ALLOGRAFT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER DISEASE; PRIORITY JOURNAL; REVIEW; SURVIVAL; VIRAL CLEARANCE;

ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; KIDNEY TRANSPLANTATION; TISSUE AND ORGAN PROCUREMENT;

EID: 79952189183     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2010.192     Document Type: Review

References (122)

1. Fabrizi, F., Messa, P., Basile, C. & Martin, P. Hepatic disorders in chronic kidney disease. Nat. Rev. Nephrol. 6, 395-403 (2010).
2. Burdick, R. A. et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int. 63, 2222-2229 (2003). (Pubitemid 36605835)
3. Johnson, D. W. et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: Analysis of registry data. Nephrol. Dial. Transplant. 24, 1598-1603 (2009).
4. Fornairon, S. et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 62, 297-299 (1996). (Pubitemid 26251300)
5. Fabrizi, F., Messa, P. & Martin, P. Hepatitis B virus infection and the dialysis patient. Semin. Dial. 21, 440-446 (2008).
6. Harnett, J. D. et al. The long-term outcome of hepatitis B infection in hemodialysis patients. Am. J. Kidney Dis. 11, 210-213 (1988). (Pubitemid 18086760)
7. Josselson, J., Kyser, B. A., Weir, M. R. & Sadler, J. H. Hepatitis B surface antigenemia in a chronic hemodialysis program: Lack of influence on morbidity and mortality. Am. J. Kidney Dis. 9, 456-461 (1987).
8. Aroldi, A. et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 79, 1132-1136 (2005). (Pubitemid 40664010)
9. Lee, W. C. et al. Long-term impact of hepatitis B, C virus infection on renal transplantation. Am. J. Nephrol. 21, 300-306 (2001).
10. Harnett, J. D. et al. Hepatitis B disease in dialysis and transplant patients. Further epidemiologic and serologic studies. Transplantation 44, 369-376 (1987). (Pubitemid 17142043)
11. Parfrey, P. S. et al. The impact of renal transplantation on the course of hepatitis B liver disease. Transplantation 39, 610-615 (1985). (Pubitemid 15066950)
12. Pirson, Y., Alexandre, G. P. & Ypersele, C. Longterm effect of hbs antigenemia on patient survival after renal transplantation. N. Engl. J. Med. 296, 194-196 (1977). (Pubitemid 8031207)
13. Hillis, W. D., Hillis, A. & Walker, W. G. Hepatitis B surface antigenemia in renal transplant recipients. increased mortality risk. JAMA 242, 329-332 (1979). (Pubitemid 9233649)
14. Fabrizi, F., Martin, P., Dixit, V., Kanwal, F. & Dulai, G. HBsAg seropositive status and survival after renal transplantation: Meta-analysis of observational studies. Am. J. Transplant. 5, 2913-2921 (2005). (Pubitemid 43923952)
15. Morales, J. M., Dominguez-Gil, B., Sanz- Guajardo, D., Fernandez, J. & escuin, F. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol. Dial. Transplant. 19 (Suppl. 3), iii72-iii76 (2004). (Pubitemid 38961443)
16. Fairley, C. K. et al. The increased risk of fatal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBV DNA positive. Transplantation 52, 497-500 (1991).
17. Breitenfeldt, M. K. et al. impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin. Transplant. 16, 130-136 (2002). (Pubitemid 34414061)
18. Hoffmann, C. J., Subramanian, A. K., Cameron, A. M. & engels, e. A. incidence and risk factors for hepatocellular carcinoma after solid organ transplantation. Transplantation 86, 784-790 (2008).
19. Fabrizi, F., Dulai, G., Dixit, V., Bunnapradist, S. & Martin, P. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: Meta-analysis of clinical trials. Transplantation 77, 859-864 (2004). (Pubitemid 38436824)
20. Goffin, e., Horsmans, Y., Cornu, C., Squifflet, J. P. & Pirson, Y. Lamivudine inhibits hepatitis B virus replication in kidney graft recipients. Transplantation 66, 407-409 (1998). (Pubitemid 28390229)
21. Kletzmayr, J. et al. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation 70, 1404-1407 (2000).
22. Lee, W. C. et al. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am. J. Kidney Dis. 38, 1074-1081 (2001).
23. Rostaing, L. et al. efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 64, 1624-1627 (1997). (Pubitemid 28047399)
24. Suzuki, Y. et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J. Hepatol. 30, 743-748 (1999). (Pubitemid 29248970)
25. Lai, C. L. et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 339, 61-68 (1998).
26. Zubkin, M. et al. Treatment of chronic hepatitis B with lamivudine in renal transplant recipients. Int. J. Artif. Organs 30, 308-314 (2007). (Pubitemid 46938855)
27. Yap, D. Y. et al. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments. Transplantation 90, 325-330 (2010).
28. Chan, T. M. et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 36, 1246-1252 (2002). (Pubitemid 35253442)
29. Han, D. J. et al. Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: Comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation 71, 387-394 (2001). (Pubitemid 32175973)
30. Chan, T. M., Tse, K. C., Tang, C. S., Lai, K. N. & Ho, S. K. Prospective study on lamivudineresistant hepatitis B in renal allograft recipients. Am. J. Transplant. 4, 1103-1109 (2004). (Pubitemid 38868601)
31. Ghany, M. G. & Doo, e. C. Antiviral resistance and hepatitis B therapy. Hepatology 49, S174-S184 (2009).
32. Chayama, K. et al. emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27, 1711-1716 (1998). (Pubitemid 28264699)
33. Gwak, G. Y. et al. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy. Transplant. Proc. 39, 3121-3126 (2007).
34. Fontaine, H. et al. efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 80, 1086-1092 (2005). (Pubitemid 41611932)
35. Hadziyannis, S. J. et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348, 800-807 (2003). (Pubitemid 36245756)
36. Marcellin, P. et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348, 808-816 (2003). (Pubitemid 36245757)
37. Perrillo, R. et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 126, 81-90 (2004). (Pubitemid 38040726)
38. izzedine, H., Launay-Vacher, V. & Deray, G. Antiviral drug-induced nephrotoxicity. Am. J. Kidney Dis. 45, 804-817 (2005). (Pubitemid 43181039)
39. Kamar, N. et al. Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients. Clin. Nephrol. 71, 36-42 (2009).
40. izzedine, H. et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies. Kidney Int. 66, 1153-1158 (2004). (Pubitemid 39121022)
41. van Bömmel, F. et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virusmonoinfected patients after failure of nucleoside/ nucleotide analogues. Hepatology 51, 73-80 (2010).
42. Neff, G. W. et al. Tenofovir therapy for lamivudine resistance following liver transplantation. Ann. Pharmacother. 38, 1999-2004 (2004). (Pubitemid 40169365)
43. Reijnders, J. G. et al. Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues. J. Hepatol. 52, 493-500 (2010).
44. Tenney, D. J. et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49, 1503-1514 (2009).
45. Kamar, N. et al. entecavir therapy for adefovirresistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 86, 611-614 (2008).
46. Liaw, Y. F. et al. 2-year GLOBe trial results: Telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136, 486-495 (2009).
47. Lai, C. L. et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 357, 2576-2588 (2007).
48. Kidney Disease: Improving Global Outcomes (KDiGO) Transplant Work Group. KDiGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant. 9 (Suppl. 3), S1-S155 (2009).
49. Kasiske, B. L. et al. KDiGO clinical practice guideline for the care of kidney transplant recipients: A summary. Kidney Int. 77, 299-311 (2010).
50. Natov, S. N. & Pereira, B. J. Transmission of viral hepatitis by kidney transplantation: Donor evaluation and transplant policies (Part 1: hepatitis B virus). Transpl. Infect. Dis. 4, 117-123 (2002). (Pubitemid 35364774)
51. Jiang, H. et al. Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: A prospective nonrandomized controlled study from a single center. Am. J. Transplant. 9, 1853-1858 (2009).
52. Cirocco, R. et al. The presence of hepatitis B core antibody does not preclude kidney donation: Lack of viral DNA in the serum and biopsies of core antibody-positive donors and clinical follow-up. Transplantation 63, 1702-1703 (1997).
53. Madayag, R. M. et al. Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. Transplantation 64, 1781-1786 (1997). (Pubitemid 28041718)
54. Wachs, M. e. et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBigM(-) organ donors. Transplantation 59, 230-234 (1995).
55. + donors: Results from a retrospective italian study. Transplantation 81, 76-80 (2006). (Pubitemid 43122152)
56. Mathurin, P. et al. impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 29, 257-263 (1999). (Pubitemid 29024011)
57. Fabrizi, F., Martin, P. & Ponticelli, C. Hepatitis C virus infection and renal transplantation. Am. J. Kidney Dis. 38, 919-934 (2001). (Pubitemid 33022168)
58. Pereira, B. J. et al. effects of hepatitis C infection and renal transplantation on survival in endstage renal disease. The New england Organ Bank Hepatitis C Study Group. Kidney Int. 53, 1374-1381 (1998).
59. Knoll, G. A., Tankersley, M. R., Lee, J. Y., Julian, B. A. & Curtis, J. J. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am. J. Kidney Dis. 29, 608-614 (1997). (Pubitemid 27155284)
60. Maluf, D. G. et al. Hepatitis C virus infection and kidney transplantation: Predictors of patient and graft survival. Transplantation 83, 853-857 (2007). (Pubitemid 46682725)
61. Fabrizi, F., Martin, P., Dixit, V., Bunnapradist, S. & Dulai, G. Hepatitis C virus antibody status and survival after renal transplantation: Meta-analysis of observational studies. Am. J. Transplant. 5, 1452-1461 (2005). (Pubitemid 40839438)
62. Stempel, C. A., Lake, J., Kuo, G. & Vincenti, F. Hepatitis C-its prevalence in end-stage renal failure patients and clinical course after kidney transplantation. Transplantation 55, 273-276 (1993). (Pubitemid 23065453)
63. espinosa, M., Martin-Malo, A., Alvarez de Lara, M. A. & Aljama, P. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol. Dial. Transplant. 16, 1669-1674 (2001). (Pubitemid 32750462)
64. Bloom, R. D. & Lake, J. R. emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. Am. J. Transplant. 6, 2232-2237 (2006). (Pubitemid 44359408)
65. Fabrizi, F. et al. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: Meta-analysis of clinical studies. Am. J. Transplant. 5, 2433-2440 (2005).
66. Vincenti, F. et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am. J. Transplant. 7, 1506-1514 (2007). (Pubitemid 46776239)
67. Burroughs, T. e. et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation 83, 1027-1034 (2007). (Pubitemid 46659113)
68. Kasiske, B. L., Snyder, J. J., Gilbertson, D. & Matas, A. J. Diabetes mellitus after kidney transplantation in the United States. Am. J. Transplant. 3, 178-185 (2003). (Pubitemid 36323115)
69. Cruzado, J. M., Carrera, M., Torras, J. & Grinyo, J. M. Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am. J. Transplant. 1, 171-178 (2001). (Pubitemid 33674158)
70. Mahmoud, i. M. et al. The impact of hepatitis C virus viremia on renal graft and patient survival: A 9-year prospective study. Am. J. Kidney Dis. 43, 131-139 (2004). (Pubitemid 38049444)
71. Hestin, D. et al. Pretransplant hepatitis C virus infection: A predictor of proteinuria after renal transplantation. Transplantation 65, 741-744 (1998). (Pubitemid 28128949)
72. Gloor, J. M. et al. Transplant glomerulopathy: Subclinical incidence and association with alloantibody. Am. J. Transplant. 7, 2124-2132 (2007). (Pubitemid 47247042)
73. Corell, A. et al. immunosuppression induced by hepatitis C virus infection reduces acute renaltransplant rejection. Lancet 346, 1497-1498 (1995).
74. Forman, J. P., Tolkoff-Rubin, N., Pascual, M. & Lin, J. Hepatitis C, acute humoral rejection, and renal allograft survival. J. Am. Soc. Nephrol. 15, 3249-3255 (2004). (Pubitemid 39578858)
75. Domínguez-Gil, B. & Morales, J. M. Transplantation in the patient with hepatitis C. Transpl. Int. 22, 1117-1131 (2009).
76. Rostaing, L. et al. impact of hepatitis C virus duration and hepatitis C virus genotypes on renal transplant patients: Correlation with clinicopathological features. Transplantation 65, 930-936 (1998). (Pubitemid 28201445)
77. Morales, J. M. & Campistol, J. M. Transplantation in the patient with hepatitis C. J. Am. Soc. Nephrol. 11, 1343-1353 (2000). (Pubitemid 30416233)
78. Kamar, N. et al. Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am. J. Transplant. 5, 1704-1712 (2005). (Pubitemid 40910453)
79. Zylberberg, H. et al. Severe evolution of chronic hepatitis C in renal transplantation: A case control study. Nephrol. Dial. Transplant. 17, 129-133 (2002). (Pubitemid 34093022)
80. izopet, J. et al. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J. Infect. Dis. 181, 852-858 (2000). (Pubitemid 30194465)
81. Alric, L. et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 123, 1494-1499 (2002). (Pubitemid 35231649)
82. Kamar, N. et al. evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J. Am. Soc. Nephrol. 14, 2092-2098 (2003). (Pubitemid 36909917)
83. Cruzado, J. M. et al. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCVRNA clearance. Am. J. Transplant. 3, 357-360 (2003). (Pubitemid 36407057)
84. Fried, M. W. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975-982 (2002).
85. Poynard, T., Yuen, M. F., Ratziu, V. & Lai, C. L. Viral hepatitis C. Lancet 362, 2095-2100 (2003). (Pubitemid 38035201)
86. Huraib, S. et al. interferon-alpha in chronic hepatitis C infection in dialysis patients. Am. J. Kidney Dis. 34, 55-60 (1999). (Pubitemid 29318796)
87. Campistol, J. M. et al. efficacy and tolerance of interferon-a2b in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol. Dial. Transplant. 14, 2704-2709 (1999). (Pubitemid 32208390)
88. Gordon, C. e. et al. interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: A systematic review of the literature and meta-analysis of treatment efficacy and harms. Am. J. Kidney Dis. 51, 263-277 (2008).
89. Gordon, C. e. et al. interferon for hepatitis C virus in hemodialysis-an individual patient meta-analysis of factors associated with sustained virological response. Clin. J. Am. Soc. Nephrol. 4, 1449-1458 (2009).
90. Kidney Disease: Improving Global Outcomes (KDiGO). KDiGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int. Suppl. 109, S1-S99 (2008).
91. Mahmoud, i. M. et al. interferon therapy in hemodialysis patients with chronic hepatitis C: Study of tolerance, efficacy and posttransplantation course. Nephron Clin. Pract. 100, c133-c139 (2005). (Pubitemid 40910990)
92. Rostaing, L. et al. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 74, 512-516 (1996). (Pubitemid 26364720)
93. Kamar, N., Ribes, D., izopet, J. & Rostaing, L. Treatment of hepatitis C virus infection (HCV) after renal transplantation: Implications for HCVpositive dialysis patients awaiting a kidney transplant. Transplantation 82, 853-856 (2006). (Pubitemid 44564028)
94. Magnone, M. et al. interferon-alpha-induced acute renal allograft rejection. Transplantation 59, 1068-1070 (1995).
95. Baid, S. et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am. J. Transplant. 3, 74-78 (2003). (Pubitemid 36306827)
96. Durlik, M. et al. Long-term results of treatment of chronic hepatitis B, C and D with interferonalpha in renal allograft recipients. Transpl. Int. 11 (Suppl. 1), S135-S139 (1998). (Pubitemid 128683526)
97. Rostaing, L. et al. Preliminary results of treatment of chronic hepatitis C with recombinant interferon alpha in renal transplant patients. Nephrol. Dial. Transplant. 10 (Suppl. 6), 93-96 (1995).
98. Shu, K. H. et al. Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation 77, 1894-1896 (2004).
99. Terrault, N. A. & Adey, D. B. The kidney transplant recipient with hepatitis C infection: Pre- and post-transplantation treatment. Clin. J. Am. Soc. Nephrol. 2, 563-575 (2007).
100. Toth, C. M. et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: Response to interferon-alpha therapy. Transplantation 66, 1254-1258 (1998). (Pubitemid 28530333)
101. Fontaine, H. et al. Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 78, 853-857 (2004). (Pubitemid 39298528)
102. Kamar, N. et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: Effects on renal function and liver histology. Am. J. Kidney Dis. 42, 184-192 (2003). (Pubitemid 36807668)
103. Kucirka, L. M. et al. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am. J. Transplant. 10, 1238-1246.
104. Morales, J. M. et al. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney Int. 47, 236-240 (1995).
105. Kasprzyk, T. et al. Long-term results of kidney transplantation from HCV-positive donors. Transplant. Proc. 39, 2701-2703 (2007). (Pubitemid 350088124)
106. Bucci, J. R. et al. Donor hepatitis C seropositivity: Clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J. Am. Soc. Nephrol. 13, 2974-2982 (2002). (Pubitemid 35386917)
107. Bucci, J. R. et al. Outcomes associated with recipient and donor hepatitis C serology status after kidney transplantation in the United States: Analysis of the USRDS/UNOS database. Clin. Transpl. 51-61 (2004).
108. Abbott, K. C. et al. The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed long-term dialysis patients. Am. J. Transplant. 4, 2032-2037 (2004). (Pubitemid 39611631)
109. Pereira, B. J., Wright, T. L., Schmid, C. H. & Levey, A. S. A controlled study of hepatitis C transmission by organ transplantation. The New england Organ Bank Hepatitis C Study Group. Lancet 345, 484-487 (1995).
110. Wolffenbüttel, L., Poli, D. D., Manfro, R. C. & Gonçalves, L. F. Cyclosporine pharmacokinetics in anti-HCV+ patients. Clin. Transplant. 18, 654-660 (2004).
111. Oo, Y. H., Dudley, T., Nightingale, P., Haydon, G. & Mutimer, D. Tacrolimus and cyclosporin doses and blood levels in hepatitis C and alcoholic liver disease patients after liver transplantation. Liver Transpl. 14, 81-87 (2008). (Pubitemid 351167993)
112. Henry, S. D. et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 131, 1452-1462 (2006). (Pubitemid 44708933)
113. Fabrizi, F., Bromberg, J., elli, A., Dixit, V. & Martin, P. Review article: hepatitis C virus and calcineurin inhibition after renal transplantation. Aliment. Pharmacol. Ther. 22, 657-666 (2005). (Pubitemid 41475328)
114. Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M. & Shimotohno, K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38, 1282-1288 (2003). (Pubitemid 37314838)
115. Schiavon, L. L. et al. impact of cyclosporinebased immunosuppressive therapy on liver histology of hepatitis C virus-infected renal transplant patients. Hepatology 48, 348-349 (2008). (Pubitemid 351975565)
116. ekberg, H. et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 357, 2562-2575 (2007). (Pubitemid 350294223)
117. Luan, F. L. et al. impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Transplantation 85, 1601-1606 (2008).
118. everson, G. T. impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl. 8, S19-S27 (2002). (Pubitemid 35154039)
119. Wiesner, R. et al. Model for end-stage liver disease (MeLD) and allocation of donor livers. Gastroenterology 124, 91-96 (2003). (Pubitemid 36055342)
120. eason, J. D. et al. Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK). Am. J. Transplant. 8, 2243-2251 (2008).
121. Nair, S., Verma, S. & Thuluvath, P. J. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 35, 1179-1185 (2002). (Pubitemid 34454015)
122. Ojo, A. O. et al. Chronic renal failure after transplantation of a nonrenal organ. N. Engl. J. Med. 349, 931-940 (2003). (Pubitemid 37064766)